TY - CHAP
T1 - Landscape of Immunotherapy in Genitourinary Malignancies
AU - Ravindranathan, Deepak
AU - Alhalabi, Omar
AU - Rafei, Hind
AU - Shah, Amishi Yogesh
AU - Bilen, Mehmet Asim
N1 - Publisher Copyright:
© 2021, The Author(s), under exclusive license to Springer Nature Switzerland AG.
PY - 2021
Y1 - 2021
N2 - The past decade has witnessed a revolution in the development of immune checkpoint inhibitors for the treatment of multiple tumor types, including genitourinary cancers. Immune checkpoint inhibitors have notably improved the treatment outcomes of patients with metastatic renal cell carcinoma and metastatic urothelial carcinoma. In prostate cancer, the role of immunotherapy with checkpoint inhibitors is not yet established except for microsatellite instability high (MSI-H) tumors. Other immunotherapeutic approaches that have been explored in these malignancies include cytokines, vaccines, and cellular therapy. Ongoing studies are exploring the use of immunotherapy combinations as well as combination with chemotherapy and targeted therapy in these types of tumors. The use of immunotherapy beyond the metastatic setting is an active area of research. Moreover, there is great interest in biomarker development to predict response to immunotherapy and risk of toxicity. This book chapter is a comprehensive review of immunotherapeutic approaches, both approved and investigational, for the treatment of renal cell carcinoma, urothelial carcinoma, and prostate cancer.
AB - The past decade has witnessed a revolution in the development of immune checkpoint inhibitors for the treatment of multiple tumor types, including genitourinary cancers. Immune checkpoint inhibitors have notably improved the treatment outcomes of patients with metastatic renal cell carcinoma and metastatic urothelial carcinoma. In prostate cancer, the role of immunotherapy with checkpoint inhibitors is not yet established except for microsatellite instability high (MSI-H) tumors. Other immunotherapeutic approaches that have been explored in these malignancies include cytokines, vaccines, and cellular therapy. Ongoing studies are exploring the use of immunotherapy combinations as well as combination with chemotherapy and targeted therapy in these types of tumors. The use of immunotherapy beyond the metastatic setting is an active area of research. Moreover, there is great interest in biomarker development to predict response to immunotherapy and risk of toxicity. This book chapter is a comprehensive review of immunotherapeutic approaches, both approved and investigational, for the treatment of renal cell carcinoma, urothelial carcinoma, and prostate cancer.
KW - Cellular therapy
KW - Checkpoint inhibitors
KW - Cytokines
KW - Immunotherapy
KW - Prostate cancer
KW - Renal cell carcinoma
KW - Urothelial carcinoma
KW - Vaccines
UR - http://www.scopus.com/inward/record.url?scp=85122438779&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85122438779&partnerID=8YFLogxK
U2 - 10.1007/978-3-030-79308-1_5
DO - 10.1007/978-3-030-79308-1_5
M3 - Chapter
C2 - 34972965
AN - SCOPUS:85122438779
T3 - Advances in Experimental Medicine and Biology
SP - 143
EP - 192
BT - Advances in Experimental Medicine and Biology
PB - Springer
ER -